133 related articles for article (PubMed ID: 17908975)
1. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.
Huang CY; Beer TM; Higano CS; True LD; Vessella R; Lange PH; Garzotto M; Nelson PS
Clin Cancer Res; 2007 Oct; 13(19):5825-33. PubMed ID: 17908975
[TBL] [Abstract][Full Text] [Related]
2. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.
Lin DW; Coleman IM; Hawley S; Huang CY; Dumpit R; Gifford D; Kezele P; Hung H; Knudsen BS; Kristal AR; Nelson PS
J Clin Oncol; 2006 Aug; 24(23):3763-70. PubMed ID: 16822846
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.
Garcia JA; Klein EA; Magi-Galluzzi C; Elson P; Triozzi P; Dreicer R
Clin Cancer Res; 2008 May; 14(10):3052-9. PubMed ID: 18483371
[TBL] [Abstract][Full Text] [Related]
4. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis.
Cheung PK; Woolcock B; Adomat H; Sutcliffe M; Bainbridge TC; Jones EC; Webber D; Kinahan T; Sadar M; Gleave ME; Vielkind J
Cancer Res; 2004 Sep; 64(17):5929-33. PubMed ID: 15342369
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of expression of growth differentiation factor 15 in normal and PIN development in the mouse.
Noorali S; Kurita T; Woolcock B; de Algara TR; Lo M; Paralkar V; Hoodless P; Vielkind J
Differentiation; 2007 Apr; 75(4):325-36. PubMed ID: 17286605
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Shepard DR; Dreicer R; Garcia J; Elson P; Magi-Galluzzi C; Raghavan D; Stephenson AJ; Klein EA
J Urol; 2009 Apr; 181(4):1672-7; discussion 1677. PubMed ID: 19230915
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer.
Halvorsen OJ; Rostad K; Øyan AM; Puntervoll H; Bø TH; Stordrange L; Olsen S; Haukaas SA; Hood L; Jonassen I; Kalland KH; Akslen LA
Clin Cancer Res; 2007 Feb; 13(3):892-7. PubMed ID: 17289882
[TBL] [Abstract][Full Text] [Related]
10. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J
Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
[TBL] [Abstract][Full Text] [Related]
11. The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer.
Satake H; Tamura K; Furihata M; Anchi T; Sakoda H; Kawada C; Iiyama T; Ashida S; Shuin T
Oncol Rep; 2010 Jan; 23(1):11-6. PubMed ID: 19956859
[TBL] [Abstract][Full Text] [Related]
12. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
[TBL] [Abstract][Full Text] [Related]
13. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
14. cDNA microarray analysis of pigment epithelium-derived factor-regulated gene expression profile in prostate carcinoma cells.
Liu W; Wu Z; Guan M; Lu Y
Int J Urol; 2009 Mar; 16(3):323-8. PubMed ID: 19207613
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
Halvorsen OJ; Oyan AM; Bø TH; Olsen S; Rostad K; Haukaas SA; Bakke AM; Marzolf B; Dimitrov K; Stordrange L; Lin B; Jonassen I; Hood L; Akslen LA; Kalland KH
Int J Oncol; 2005 Feb; 26(2):329-36. PubMed ID: 15645116
[TBL] [Abstract][Full Text] [Related]
16. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
Walton TJ; Li G; McCulloch TA; Seth R; Powe DG; Bishop MC; Rees RC
Prostate; 2009 Jun; 69(8):810-9. PubMed ID: 19189301
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of PC-3 cell line variants and comparison of MIC-1 transcript levels in benign and malignant prostate.
Patrikainen L; Porvari K; Kurkela R; Hirvikoski P; Soini Y; Vihko P
Eur J Clin Invest; 2007 Feb; 37(2):126-33. PubMed ID: 17217378
[TBL] [Abstract][Full Text] [Related]
18. Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis.
Narita S; Tsuchiya N; Saito M; Inoue T; Kumazawa T; Yuasa T; Nakamura A; Habuchi T
Prostate; 2008 Feb; 68(3):321-35. PubMed ID: 18175332
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
Gordon RR; Wu M; Huang CY; Harris WP; Sim HG; Lucas JM; Coleman I; Higano CS; Gulati R; True LD; Vessella R; Lange PH; Garzotto M; Beer TM; Nelson PS
PLoS One; 2014; 9(9):e104271. PubMed ID: 25198178
[TBL] [Abstract][Full Text] [Related]
20. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
